List of Excipients in Branded Drug CABERGOLINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	CABERGOLINE	cabergoline	59762-1005	LACTOSE
Mylan Pharmaceuticals Inc	CABERGOLINE	cabergoline	59762-1005	LEUCINE

Generic Drugs Containing CABERGOLINE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	cabergoline	0093-5420	ANHYDROUS LACTOSE
Teva Pharmaceuticals USA Inc	cabergoline	0093-5420	LEUCINE
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	cabergoline	23155-823	CELLULOSE, MICROCRYSTALLINE
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	cabergoline	23155-823	CITRIC ACID MONOHYDRATE

What are the Most Frequently-Used Excipients in CABERGOLINE?

# Of NDCs	Excipient
5	ANHYDROUS CITRIC ACID
3	ANHYDROUS LACTOSE
13	CELLULOSE, MICROCRYSTALLINE
8	CITRIC ACID MONOHYDRATE

Last updated: August 22, 2026

Cabergoline is a mature, low-cost generic dopamine agonist with limited compound-patent protection and no biosimilar exposure. Commercial value is concentrated in differentiated oral dosage forms, improved content uniformity for the 0.25 mg dose, patient-friendly administration, veterinary products, and geographically tailored regulatory filings. The principal development barrier is clinical and regulatory positioning, not active-molecule exclusivity.

Cabergoline Excipient Strategy and Commercial Opportunities

What is cabergoline used for and how is it marketed?

Cabergoline is an ergot-derived dopamine D2 receptor agonist. In the United States, the FDA-approved indication for Dostinex and generic cabergoline tablets is the treatment of hyperprolactinemic disorders, including idiopathic hyperprolactinemia and hyperprolactinemia associated with pituitary adenomas.

The usual starting regimen is 0.25 mg twice weekly. The dose can be increased based on serum prolactin response, generally at intervals of at least four weeks. Tablets are commonly supplied at 0.5 mg, creating a commercial need for reliable tablet subdivision or a lower-strength presentation. [1]

Cabergoline is also used internationally and in veterinary medicine. Uses outside the U.S. label include suppression of lactation, treatment of reproductive disorders, and management of pseudopregnancy in dogs. These uses create potential markets, but they require separate regulatory strategies and evidence packages.

Attribute	Cabergoline commercial profile
Active ingredient	Cabergoline
Pharmacology	Dopamine D2 receptor agonist
Main U.S. indication	Hyperprolactinemic disorders
Common strength	0.5 mg tablet
Typical starting dose	0.25 mg twice weekly
Originator brand	Dostinex
U.S. regulatory status	Generic immediate-release tablets approved
Biologic status	Not applicable
Primary commercial issue	Price competition and limited differentiation
Main formulation opportunity	Low-dose, patient-friendly oral dosage forms

When did cabergoline lose exclusivity?

Cabergoline lost meaningful U.S. market exclusivity years ago. The original product was approved by the FDA in December 1996, and the principal composition-of-matter patent was not a current barrier to generic entry by the time generic products entered the U.S. market.

The historical cabergoline patent estate included U.S. Patent No. 4,526,892, which covered cabergoline-related chemical matter. Its ordinary patent term expired before the current generic market developed. The product is now supplied by multiple generic manufacturers, including companies that have held or marketed U.S. abbreviated new drug applications.

The commercial consequence is material:

• New cabergoline products generally cannot rely on compound exclusivity.
• A standard 0.5 mg immediate-release tablet is difficult to protect through formulation patents alone.
• Regulatory exclusivity is unlikely to create a durable commercial moat for a conventional generic.
• Value must come from manufacturing economics, differentiated dosage forms, supply reliability, or a separately supported indication.

Cabergoline exclusivity timeline

Event	Approximate date	Commercial significance
Core cabergoline patent filing and prosecution	1980s	Established chemical-entity protection
U.S. Patent No. 4,526,892 issued	1985	Historical composition protection
Dostinex FDA approval	1996	Established U.S. reference product
Core patent expiry	2000s	Removed principal compound barrier
Generic cabergoline entry	2000s onward	Created price-based competition
Current market	2020s	Mature generic and specialty-formulation opportunity

Exact patent-term calculations can vary because of patent-term adjustment, patent-term extension, and jurisdiction-specific rules. Those provisions do not change the current conclusion that cabergoline is an off-patent small molecule in the U.S. market.

What patents protect cabergoline products today?

The active-molecule patent estate is no longer the main protection strategy. Potentially relevant rights now fall into four categories:

1. Formulation patents covering orally disintegrating tablets, modified-release systems, taste-masked products, or alternate solid forms.
2. Method-of-use patents covering particular patient populations or dosing schedules.
3. Manufacturing patents covering crystallization, purification, particle engineering, or impurity control.
4. Device or packaging rights associated with unit-dose presentation and tablet splitting.

A formulation patent must provide more than a conventional mixture of cabergoline and standard excipients. For enforceability, the applicant would normally need a defined technical feature, such as a specific disintegration profile, stability improvement, dose-uniformity result, dissolution profile, or manufacturing process.

How strong is the cabergoline patent estate?

The estate is weak for conventional immediate-release tablets and potentially stronger for technically differentiated products.

Product concept	Patent strength	Commercial assessment
Conventional 0.5 mg tablet	Low	Commodity generic market
0.25 mg tablet	Low to moderate	Useful product differentiation, limited patent durability
Orally disintegrating tablet	Moderate	Potential formulation and process claims
Chewable or taste-masked tablet	Moderate	Patient-use advantage if palatability is demonstrated
Modified-release product	Moderate to high	Requires clinical bridging and meaningful pharmacokinetic differentiation
Veterinary palatable formulation	Moderate	Separate formulation, packaging, and market claims possible
New indication	Moderate to high	Requires clinical data and method-of-use protection
Novel salt or polymorph	Variable	Must show technical or pharmaceutical advantage

Patent protection is more credible when the formulation solves a measurable problem. Cabergoline’s low dose makes content uniformity, tablet splitting, and dose administration more defensible development targets than a generic claim to “improved convenience.”

What excipients are used in cabergoline tablets?

The U.S. Dostinex tablet contains cabergoline with lactose and leucine as inactive ingredients, according to the FDA labeling information. Generic formulations can use different excipients if they meet quality, bioequivalence, and regulatory requirements. [1,2]

A commercial formulation must account for the following properties:

• Very low dose relative to tablet mass.
• Need for accurate subdivision when patients receive 0.25 mg.
• Potential sensitivity to blend segregation and sampling error.
• Low aqueous solubility and the need for reproducible dissolution.
• Possible sensitivity to light, heat, moisture, and oxidative degradation.
• Ergot-derived pharmacology, which places a high premium on dose accuracy.

The low active load is the central formulation issue. In a 0.5 mg tablet, cabergoline may represent a small fraction of total tablet weight. Direct blending is possible, but the process must control segregation and ensure uniform distribution through compression and packaging.

Which excipient strategy is best for cabergoline?

The preferred strategy depends on the target dosage form. A conventional tablet should prioritize blend uniformity, low-dose potency control, mechanical strength, and predictable dissolution. An orally disintegrating tablet should prioritize rapid wetting, acceptable mouthfeel, and low friability.

Conventional immediate-release tablet

A practical platform may combine:

• Lactose monohydrate or spray-dried lactose as a diluent.
• Microcrystalline cellulose for compactability.
• Crospovidone or croscarmellose sodium as a disintegrant.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate at a controlled concentration and lubrication time.
• Leucine where improved powder flow or mouthfeel is required.

Wet granulation may improve content uniformity and reduce segregation, but it introduces water and heat exposure. Direct compression may reduce processing complexity but demands stronger control of particle size, density, and blend homogeneity.

For a 0.5 mg product, the highest-value development work is usually not the selection of a novel excipient. It is the validated distribution of cabergoline throughout the blend and the control of low-dose assay variability.

0.25 mg tablet

A dedicated 0.25 mg tablet could offer a practical advantage over splitting a 0.5 mg tablet. The product would need to demonstrate:

• Content uniformity at the lower dose.
• Adequate tablet robustness.
• Reliable dissolution.
• Accurate handling by patients and pharmacies.
• A commercially acceptable tablet size.

A 0.25 mg product could be positioned for initial titration and dose reduction. It may also reduce medication errors caused by tablet splitting. The regulatory route would likely be an ANDA if the product can meet the relevant reference-product requirements, although a lower-strength product requires careful assessment of proportional composition, dissolution, and bioequivalence expectations.

Orally disintegrating tablet

An orally disintegrating tablet could address swallowing difficulty, administration without water, and veterinary use. Mannitol is often useful for mouthfeel and rapid dissolution. Crospovidone, low-substituted hydroxypropyl cellulose, or other disintegrants can support rapid breakup. A taste-masking approach may be needed because cabergoline can produce an unpleasant oral sensory profile.

Potential formulation claims could cover:

• A defined disintegration time.
• Improved palatability.
• Reduced tablet friability.
• A specific particle-engineering or granulation process.
• Improved dose uniformity at 0.25 mg or 0.5 mg.
• A defined dissolution profile under discriminatory conditions.

The product would face a high bioequivalence burden if the dosage form changes absorption rate or extent. A fast-disintegrating tablet is not automatically therapeutically differentiated.

What formulations are commercially protected by cabergoline patents?

The most defensible formulation opportunities are those linked to a specific technical effect. Examples include:

Low-dose uniformity formulations

A formulation designed for highly uniform distribution of 0.25 mg or 0.5 mg cabergoline could support process and composition claims. The data package should compare blend uniformity, tablet-to-tablet assay, segregation risk, and content-uniformity performance against a conventional direct-compression formulation.

Taste-masked formulations

Taste masking may be valuable for orally disintegrating and veterinary products. Protection could involve coated particles, ion-exchange complexes, lipid barriers, polymer matrices, or a specific combination of sweeteners and flavoring agents. The claims would need sensory and dissolution data.

Veterinary palatable tablets

Veterinary products can use flavor systems, chewable matrices, unit-dose packaging, and species-specific administration instructions. A dog-focused formulation for pseudopregnancy or lactation-related conditions could create a commercial niche, although veterinary regulatory requirements and market authorization differ by country.

Stability-enhanced formulations

A formulation that materially improves stability under heat, humidity, or light stress could support commercial value in emerging markets and supply chains with limited cold-chain or climate control. Cabergoline is generally supplied as a room-temperature solid oral product, so any stability claim must demonstrate a measurable improvement over existing products.

What is the Orange Book status of cabergoline?

Cabergoline is an FDA-listed small-molecule product, not a biologic. Generic versions are approved through the ANDA pathway and are subject to Orange Book therapeutic-equivalence listings where applicable.

The practical Orange Book position is:

• Dostinex is the historical reference listed drug.
• Generic cabergoline tablets have been approved in equivalent strengths.
• There is no biosimilar pathway.
• A new formulation may not qualify for automatic substitution if it has a different dosage form, route, or release profile.
• Any current Orange Book patent listing must be checked at the time of filing because listings can change with reference-product supplements and FDA database updates. [3]

For a differentiated formulation, the regulatory strategy may be either an ANDA referencing the listed drug or a 505(b)(2) application, depending on the formulation, clinical data, and reliance on existing findings. A materially different release profile or delivery system increases the likelihood of a 505(b)(2) pathway and additional clinical requirements.

Are there Paragraph IV challenges for cabergoline?

Paragraph IV litigation is not the principal current risk for conventional cabergoline because the original compound patents expired long ago and multiple generic products are already marketed.

A new formulation could create a different litigation profile if it relies on:

• A listed method-of-use patent.
• A formulation patent listed for a reference product.
• A release-profile patent.
• A device or packaging patent.
• A patent covering a particular patient population.

For a standard generic, the principal launch risks are regulatory deficiency, manufacturing economics, product liability, supply disruption, and market price erosion. For an improved formulation, patent certification and 30-month-stay exposure must be evaluated against the specific Orange Book listing and application strategy.

What patent litigation and settlement agreements affect cabergoline?

No major continuing U.S. patent litigation or settlement structure is central to the current conventional cabergoline market. The market matured after expiration of the principal originator protection.

A new entrant should still screen:

• District court records for active formulation disputes.
• Federal Circuit decisions involving cabergoline formulations.
• ANDA litigation involving any newly listed patents.
• Regulatory exclusivity attached to a new indication or dosage form.
• Licensing agreements related to drug delivery, taste masking, or veterinary distribution.

The absence of a major current litigation barrier is commercially favorable for generic entry but reduces the value of acquiring a legacy cabergoline patent portfolio.

Which companies are challenging or competing with cabergoline?

Competition comes from three groups:

1. Generic cabergoline manufacturers.
2. Alternative dopamine agonists, principally bromocriptine.
3. Other treatment approaches for hyperprolactinemia, including surgery for selected pituitary tumors and treatment of underlying causes.

Cabergoline has a dosing advantage over bromocriptine because it is commonly administered twice weekly rather than daily. That advantage supports adherence but does not prevent price competition.

Competitive factor	Cabergoline	Bromocriptine
Dosing frequency	Often twice weekly	Usually daily or more frequently
Generic availability	Broad	Broad
Main clinical use	Hyperprolactinemia	Hyperprolactinemia and other uses
Differentiation opportunity	ODT, 0.25 mg, veterinary	Formulation and tolerability
Patent barrier	Low	Low for mature products
Key commercial issue	Low price and supply reliability	Tolerability and dosing burden

Manufacturer shares and revenue exposure change by country and procurement channel. Because cabergoline is generic, product-level revenue data are less transparent than for branded medicines. A formulation developer should model net price, not historical branded sales.

What revenue exposure exists for cabergoline?

Cabergoline revenue is exposed to rapid generic price erosion. A conventional tablet may have meaningful volume but limited gross margin. Commercial returns improve when the product has one of the following characteristics:

• A protected or difficult-to-copy dosage form.
• A reliable 0.25 mg presentation.
• A veterinary authorization.
• A shortage-sensitive supply position.
• Direct sales in markets with fragmented generic competition.
• A licensed formulation platform that can be reused across low-dose drugs.

The most attractive business model may be a platform product rather than a single generic SKU. A company with expertise in low-dose blending, orally disintegrating tablets, or palatability enhancement could use cabergoline as an entry product and apply the same manufacturing process to other potent oral drugs.

What manufacturing and IP barriers exist for cabergoline?

The principal manufacturing barriers are process control and analytical sensitivity.

Critical controls include:

• Homogeneous distribution of a low-dose active ingredient.
• Prevention of segregation during transfer and compression.
• Control of lubricant concentration and blending time.
• Stability-indicating assay and impurity methods.
• Protection from light and humidity where required.
• Tablet-splitting performance for 0.5 mg tablets.
• Batch-scale reproducibility.

A robust control strategy should include blend uniformity sampling, in-process tablet-weight controls, content-uniformity testing, dissolution testing, and degradation monitoring. Packaging can include high-density polyethylene containers with desiccant or other moisture-control systems, subject to stability data.

Manufacturing know-how may be more valuable than patent rights. A competitor can often design around a narrow excipient claim, but reproducing a validated low-dose process with consistent commercial yields is harder.

What generic launch scenarios exist for cabergoline?

Standard generic launch

This is the lowest-risk pathway but also the lowest-margin option. The product competes mainly on price, supply, and wholesaler access.

0.25 mg dedicated strength

This approach targets initial titration and dose adjustment. It may support modest price differentiation if the product reduces tablet-splitting errors and is adopted by endocrinologists.

Orally disintegrating or chewable product

This approach targets swallowing difficulty, adherence, and veterinary administration. It has stronger differentiation potential but may require additional bioequivalence, palatability, and stability work.

505(b)(2) delivery system

A modified-release or otherwise novel delivery system could support stronger intellectual-property protection. The clinical development burden and reimbursement uncertainty are substantially higher.

Veterinary product

A palatable veterinary dosage form could avoid direct substitution with human generic tablets. The opportunity depends on country-specific veterinary approval, distribution, and labeling requirements.

How does cabergoline compare with other generic formulation opportunities?

Cabergoline is attractive for low-dose formulation development because the active dose is small and dose uniformity is commercially relevant. It is less attractive for a pure commodity launch because multiple generic products already exist and the originator market is mature.

Criterion	Cabergoline	Typical high-volume generic
Compound-patent risk	Low	Variable
Formulation complexity	Moderate	Low to moderate
Dose-uniformity challenge	High	Variable
Patient convenience opportunity	Moderate	Variable
Biosimilar risk	None	None for small molecules
Price erosion risk	High	High
Specialty-formulation upside	Moderate	Variable
Veterinary opportunity	Meaningful	Product-specific

Key Takeaways

• Cabergoline is an off-patent small molecule with extensive generic competition.
• The historical core patent estate, including U.S. Patent No. 4,526,892, no longer blocks conventional entry.
• The strongest commercial formulation opportunity is a reliable 0.25 mg product or an orally disintegrating dosage form.
• Excipient selection should prioritize content uniformity, segregation control, dissolution, palatability, and stability.
• Lactose, leucine, microcrystalline cellulose, mannitol, crospovidone, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate are practical platform excipients, subject to formulation and regulatory testing.
• A novel excipient combination alone is unlikely to create durable protection without demonstrated technical performance.
• Cabergoline has no biosimilar risk because it is a synthetic small molecule.
• Paragraph IV risk is limited for standard products but can arise for newly patented formulations or methods of use.
• Veterinary palatable products and low-dose administration systems offer the clearest niche opportunities.
• Manufacturing know-how may provide greater commercial protection than a narrow formulation patent.

FAQs

Can cabergoline be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could use mannitol, a superdisintegrant, flavoring, and a taste-masking system. The product would require evidence of dose uniformity, dissolution, stability, mechanical strength, and bioequivalence.

Is a 0.25 mg cabergoline tablet commercially attractive?

It can be attractive because the usual starting dose is 0.25 mg twice weekly. A dedicated strength may reduce tablet-splitting errors, but commercial value depends on reimbursement, prescribing behavior, and manufacturing cost.

Does cabergoline require a biosimilar application?

No. Cabergoline is a chemically synthesized small molecule. A generic product is generally pursued through an ANDA, while a materially different delivery system may require a 505(b)(2) application.

Can excipient changes trigger a new clinical study?

They can. Minor excipient changes may be addressed through pharmaceutical equivalence, comparative dissolution, and bioequivalence work. A new dosage form, release profile, route, or absorption pattern can require additional clinical or pharmacokinetic studies.

Is veterinary cabergoline a separate licensing opportunity?

Yes. A veterinary product can use species-appropriate palatability, dosing, packaging, and labeling. It requires compliance with the applicable veterinary regulatory pathway and cannot rely automatically on a human-product approval.

References

1. U.S. Food and Drug Administration. (2019). Dostinex (cabergoline) tablets prescribing information. FDA.
2. National Library of Medicine. (2024). Cabergoline tablet: DailyMed labeling database. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. United States Patent and Trademark Office. (1985). U.S. Patent No. 4,526,892: Cabergoline-related ergoline compounds. USPTO.
5. European Medicines Agency. (2024). Cabergoline-containing medicinal products and product information. EMA.